(CercleFinance.com) – Innate Pharma announces that the first preclinical data relating to IPH45, its exatecan-based antibody-drug conjugate (ADC), were presented at the 2024 annual meeting of the American Association for Research on Cancer. cancer (AACR).
In preclinical models of bladder tumors, data show improved activity of IPH45 compared to enfortumab vedotin (EV). It also shows antitumor efficacy in different solid tumor models, including those refractory to EV.
‘Based on these preclinical efficacy and toxicology data, the development of IPH45 is continuing towards the clinical phase with the submission of a clinical trial application expected in 2024’, adds the biopharmaceutical company.